Jennifer Woiwode
Psychiatric/Mental Health · Minot, NDNPI 1437795796
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.5% of the total across 139 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 14 manufacturers, the largest accounting for just 20.8% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $636 and has fallen 83.6% since, to $104 in 2025. Among psychiatric/mental health clinicians in ND with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 139 payments — averaging $17.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$509
- Alkermes, Inc.$410
- Lundbeck LLC$387
- AbbVie$338
- Sunovion Pharmaceuticals Inc.$279
- Teva Pharmaceuticals USA, Inc.$173
- plus $353 from 8 others
What the payments were for
- Food & beverage$2,435100%
- Education$120%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 25 | $509 |
| Alkermes, Inc. | 26 | $410 |
| Lundbeck LLC | 21 | $387 |
| AbbVie(2 entities) | 17 | $338 |
| Sunovion Pharmaceuticals Inc. | 20 | $279 |
| Teva Pharmaceuticals USA, Inc. | 10 | $173 |
| Takeda Pharmaceuticals U.S.A., Inc. | 5 | $98 |
| Otsuka America Pharmaceutical, Inc. | 4 | $66 |
| Axsome Therapeutics, Inc. | 3 | $53 |
| Neurocrine Biosciences, Inc. | 2 | $40 |
| Acadia Pharmaceuticals Inc | 2 | $30 |
| Sage Therapeutics, LLC | 2 | $30 |
| Supernus Pharmaceuticals, Inc. | 1 | $22 |
| Jazz Pharmaceuticals Inc. | 1 | $13 |
How this compares
$2,447 in reported general payments places this provider in the 90th percentile of 92 psychiatric/mental health providers in North Dakota.
See all psychiatric/mental health providers in North Dakota →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| NuplazidPimavanserin Tartrate | 11 | $46,693 |
| Invega SustennaPaliperidone Palmitate | 12 | $42,971 |
| VraylarCariprazine Hcl | 11 | $16,000 |
| Eszopiclone | 33 | $3,461 |
| Divalproex Sodium ErDivalproex Sodium | 26 | $2,831 |
| Guanfacine Hcl ErGuanfacine Hcl | 13 | $1,864 |
| Citalopram HbrCitalopram Hydrobromide | 14 | $1,058 |
| Quetiapine Fumarate | 59 | $1,016 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 19 | $666 |
| Fluoxetine Hcl | 36 | $510 |
| Prazosin Hcl | 22 | $494 |
| Aripiprazole | 22 | $488 |
| Paroxetine Hcl | 13 | $463 |
| Clonazepam | 23 | $387 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 12 | $253 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Acadia Pharmaceuticals IncNuplazid | $30 | $46,69311 claims |
| AbbVieVraylar | $338 | $16,00011 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 92 psychiatric/mental health providers in North Dakota.
Other psychiatric/mental health in Minot
- Roxann BrownMinot$3K
- Tonya AndersonMinot$3K
- Bobbie BusethMinot$2K
- Tammy UlebergMinot$2K
- Kiley AndreasMinot$2K
- Stacy FlatenMinot$987
- Pamela WallsMinot$823
- Melissa ScheppMinot$797
- Alicja CebulakMinot$661
- Amanda DaggettMinot$545
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.